The protein encoded by this gene is a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. This phosphoprotein localizes to nuclear bodies (Nuclear dots) where it functions as a transcription factor and tumor suppressor. Its expression is cell-cycle related and it regulates the p53 response to oncogenic signals. The gene is often involved in the translocation with the retinoic acid receptor alpha gene associated with acute promyelocytic leukemia (APL). Extensive alternative splicing of this gene results in several variations of the protein's central and C-terminal regions; all variants encode the same N-terminus. Alternatively spliced transcript variants encoding different isoforms have been identified.
^Kojic S, Medeot E, Guccione E, Krmac H, Zara I, Martinelli V et al. (May 2004). "The Ankrd2 protein, a link between the sarcomere and the nucleus in skeletal muscle". J. Mol. Biol.339 (2): 313–25. doi:10.1016/j.jmb.2004.03.071. PMID15136035.
^ abZhong S, Delva L, Rachez C, Cenciarelli C, Gandini D, Zhang H et al. (Nov 1999). "A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins". Nat. Genet.23 (3): 287–95. doi:10.1038/15463. PMID10610177.
^Topcu Z, Mack DL, Hromas RA, Borden KL (Nov 1999). "The promyelocytic leukemia protein PML interacts with the proline-rich homeodomain protein PRH: a RING may link hematopoiesis and growth control". Oncogene18 (50): 7091–100. doi:10.1038/sj.onc.1203201. PMID10597310.
^Shin J, Park B, Cho S, Lee S, Kim Y, Lee SO et al. (Sep 2004). "Promyelocytic leukemia is a direct inhibitor of SAPK2/p38 mitogen-activated protein kinase". J. Biol. Chem.279 (39): 40994–1003. doi:10.1074/jbc.M407369200. PMID15273249.
^Zhu H, Wu L, Maki CG (Dec 2003). "MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53". J. Biol. Chem.278 (49): 49286–92. doi:10.1074/jbc.M308302200. PMID14507915.
^Wei X, Yu ZK, Ramalingam A, Grossman SR, Yu JH, Bloch DB et al. (Aug 2003). "Physical and functional interactions between PML and MDM2". J. Biol. Chem.278 (31): 29288–97. doi:10.1074/jbc.M212215200. PMID12759344.
^Wu WS, Xu ZX, Ran R, Meng F, Chang KS (May 2002). "Promyelocytic leukemia protein PML inhibits Nur77-mediated transcription through specific functional interactions". Oncogene21 (24): 3925–33. doi:10.1038/sj.onc.1205491. PMID12032831.
^Kawasaki A, Matsumura I, Kataoka Y, Takigawa E, Nakajima K, Kanakura Y (May 2003). "Opposing effects of PML and PML/RAR alpha on STAT3 activity". Blood101 (9): 3668–73. doi:10.1182/blood-2002-08-2474. PMID12506013.
^Lin DY, Shih HM (Jul 2002). "Essential role of the 58-kDa microspherule protein in the modulation of Daxx-dependent transcriptional repression as revealed by nucleolar sequestration". J. Biol. Chem.277 (28): 25446–56. doi:10.1074/jbc.M200633200. PMID11948183.
^Kamitani T, Nguyen HP, Kito K, Fukuda-Kamitani T, Yeh ET (Feb 1998). "Covalent modification of PML by the sentrin family of ubiquitin-like proteins". J. Biol. Chem.273 (6): 3117–20. doi:10.1074/jbc.273.6.3117. PMID9452416.
^Takahashi H, Hatakeyama S, Saitoh H, Nakayama KI (Feb 2005). "Noncovalent SUMO-1 binding activity of thymine DNA glycosylase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein". J. Biol. Chem.280 (7): 5611–21. doi:10.1074/jbc.M408130200. PMID15569683.
Combes R, Balls M, Bansil L, Barratt M, Bell D, Botham P et al. (2002). "An assessment of progress in the use of alternatives in toxicity testing since the publication of the report of the second FRAME Toxicity Committee (1991)". Alternatives to laboratory animals : ATLA30 (4): 365–406. PMID12234245.